Compare BRID & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | ACET |
|---|---|---|
| Founded | 1932 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 71.3M |
| IPO Year | 1995 | 2017 |
| Metric | BRID | ACET |
|---|---|---|
| Price | $7.48 | $7.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 1.6K | ★ 184.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $174,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $7.24 | $0.45 |
| 52 Week High | $10.77 | $9.05 |
| Indicator | BRID | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 55.48 |
| Support Level | $7.43 | $6.50 |
| Resistance Level | $7.73 | $7.30 |
| Average True Range (ATR) | 0.24 | 0.63 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 10.68 | 50.09 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.